Further Considerations. None of the Parties shall have any obligation to the other Parties with respect to any license fees, milestone payments, royalties, or any other financial consideration received by a Party pursuant to a sublicense or license.
Appears in 3 contracts
Sources: Cross License Agreement (Biotime Inc), Cross License Agreement (Biotime Inc), Cross License Agreement (Asterias Biotherapeutics, Inc.)